Bremelanotide, widely referenced in clinical settings by its research designation PT-141, is a synthetic melanocortin receptor agonist peptide. It is the active ingredient in an FDA-approved injectable product and is also ordered in compounded forms by clinics that offer sexual-wellness services under individualized prescribing.
PT-141 ranks as the #15 most-prescribed compounded product on ScriptLinkRx, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. Its position on the platform reflects steady demand from sexual-wellness and men's/women's health practices, alongside a regulatory profile that is more nuanced than most peptides because an approved reference product already exists.
What PT-141 (Bremelanotide) Is
Bremelanotide is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, with activity at the melanocortin-4 receptor (MC4R) of primary interest in the context of sexual desire. It is a synthetic analog derived from the earlier peptide melanotan II. Unlike vasoactive agents that work on peripheral blood flow, bremelanotide is understood to act centrally on melanocortin pathways in the nervous system.
Per the FDA-approved labeling for the branded injectable product, the precise mechanism by which bremelanotide acts on sexual desire and related distress is not fully established. Providers evaluating the compound should treat central-melanocortin activity as the mechanistic frame rather than a claim of a specific clinical outcome.
How Providers Use It in Practice
PT-141 is ordered chiefly by clinics operating in the sexual-wellness and hormone-optimization space, including men's health practices, women's health and gynecology-adjacent clinics, and integrative or longevity-oriented providers. In practice it is prescribed in the context of low sexual desire or arousal concerns, under an individual prescriber's clinical judgment.
The FDA-approved indication for branded bremelanotide is narrow: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Any use outside that population — including use in men, in postmenopausal women, or via routes other than the approved subcutaneous injection — is off-label. Off-label prescribing is a decision that rests with the licensed prescriber for a specific patient; it is not something a pharmacy, a platform, or an educational resource can promote or recommend. Clinics order compounded medications through platforms like ScriptLinkRx, but the clinical rationale for any given prescription remains the provider's responsibility.
Forms and Combinations Available Through Compounding
The FDA-approved reference product is a subcutaneous injection delivered by autoinjector. Compounding pharmacies may prepare bremelanotide in a range of dosage forms depending on prescriber orders and the pharmacy's capabilities, which can include:
- Subcutaneous injectable solutions in patient-specific concentrations
- Intranasal formulations
- Oral capsules
- Sublingual troches or rapid-dissolve tablets — most often encountered as multi-ingredient combination products rather than standalone bremelanotide
The stated rationale for compounding is patient-specific customization — for example, a concentration or route not available in the commercial product, or a formulation addressing a documented patient need such as an allergy or intolerance to a component of the approved product. Compounded formulations are prepared for an individual patient pursuant to a valid prescription; they are not mass-produced or held out as interchangeable with the approved drug.
This resource does not provide dosing, titration, or administration instructions. Those parameters are determined by the prescribing clinician and the compounding pharmacy consistent with applicable standards.
Regulatory Status and Provider Considerations
Bremelanotide occupies an unusual regulatory position because an FDA-approved product containing it already exists. This is the single most important fact for any clinic considering compounded PT-141.
- An approved product exists. The FDA approved branded bremelanotide (marketed as Vyleesi) on June 21, 2019, for acquired, generalized HSDD in premenopausal women, as a subcutaneous injection administered by autoinjector. As of July 2026, this remains the only FDA-approved bremelanotide product and the only FDA-approved indication.
- Compounded PT-141 is not FDA-approved. Compounded bremelanotide has not been evaluated by the FDA for safety, efficacy, or manufacturing quality, and it is not equivalent to or interchangeable with the approved product. It should never be represented to patients as FDA-approved.
- The "essentially a copy" analysis applies. Because an approved drug exists, a 503A pharmacy compounding bremelanotide must contend with the "essentially a copy of a commercially available drug product" restriction. In general terms, this means the prescriber is expected to document a clinical difference — for the specific patient — between the compounded preparation and the approved product (for example, a change in dosage form, strength, or route that produces a significant difference for that patient as determined by the prescriber). A different route (such as intranasal or sublingual) or a customized concentration may factor into that analysis, but the individualized clinical justification is the prescriber's responsibility and should be documented in the patient record.
- Off-label populations and routes. Use in men, in postmenopausal women, or through non-approved routes falls outside the approved indication. Regulatory facts about the approved indication do not constitute an endorsement of uses beyond it.
- 503B considerations differ. Outsourcing facilities operating under section 503B are governed by a separate framework (including the 503B bulk drug substances list) and are subject to cGMP requirements. Clinics should understand which pathway a given pharmacy is using.
Providers should confirm the current status directly, as compounding policy for peptides has been in active flux. Nothing in this overview should be read as legal or regulatory advice.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Because compounded PT-141 is not FDA-reviewed, sourcing diligence falls to the prescribing clinic. A practical checklist:
- API source and Certificate of Analysis (CoA). Ask where the bremelanotide active pharmaceutical ingredient is sourced, and request a lot-specific CoA documenting identity and purity.
- USP compliance. Confirm the pharmacy compounds to the applicable USP chapters — <795> for nonsterile preparations and <797> for sterile preparations (relevant for any injectable), plus <800> where hazardous-drug handling applies.
- Potency and sterility testing. For injectables, ask about sterility testing, endotoxin testing, and potency/assay verification, and whether testing is performed in-house or by an accredited third-party lab.
- Beyond-use dating (BUD). Request the assigned BUD and the basis for it (stability data versus default USP limits).
- State licensure and inspection history. Verify the pharmacy is licensed in your state, in good standing, and — if applicable — registered as a 503B outsourcing facility. Understand whether you are receiving patient-specific 503A preparations or 503B stock.
- Formulation transparency. Confirm the exact formulation, concentration, preservative system, and route so the preparation matches the prescription and the documented clinical rationale.
Frequently Asked Questions
Is compounded PT-141 FDA-approved?
No. Compounded bremelanotide is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. An FDA-approved bremelanotide injection exists for a specific indication, but compounded preparations are distinct, are made pursuant to individual prescriptions, and are not interchangeable with the approved product.
Can PT-141 be compounded if there is already an approved bremelanotide product?
Compounding of a drug for which an approved product exists is subject to the "essentially a copy" restriction under section 503A. In general, the prescriber is expected to document a patient-specific clinical difference — such as an altered strength, dosage form, or route — that the approved product cannot meet. That documentation and the underlying clinical judgment are the prescriber's responsibility.
Is use in men or via nasal/sublingual routes off-label?
Yes. As of July 2026 the only FDA-approved indication is acquired, generalized HSDD in premenopausal women, using the approved subcutaneous injection. Use in other populations or by other routes is off-label. Off-label prescribing is a clinical decision for the licensed prescriber and cannot be promoted.
What quality documentation should a clinic keep on file?
At minimum, retain the lot-specific Certificate of Analysis, evidence of USP <795>/<797> compliance, sterility and potency testing results for injectables, the assigned beyond-use date, and confirmation of the pharmacy's state licensure and 503A/503B status.
Related Reading
- See where PT-141 ranks among the most-prescribed compounded medications
- Compounded oxytocin: forms and provider considerations
Sources
- FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women (FDA, 2019)
- VYLEESI (bremelanotide injection) Prescribing Information — Initial U.S. Approval: 2019 (accessdata.fda.gov)
- Bremelanotide NDA Approval Package (accessdata.fda.gov)
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire Disorder (NIH/PMC)
